Clinical Presentations

In this week's Homerun Slides, the safety warnings, precautions, and incorporation of SGLT-2 inhibitors into diabetes treatment.

In this week's Homerun Slides, talking to patients about SGLT-2 as a treatment option.

In this week's Homerun Slides, the implications for practice and conclusion of the EMPA-REG Outcome Trial.

In this week's Homerun Slides, the ratios of the adverse events in patients and their tolerability of the placebo vs empagliflozin.

In this week's Homerun Slides, the rate of heart failure hospitalization and all-cause mortality of patients on the placebo vs empagliflozin study.

In this week's Homerun Slides, the cardiovascular outcomes of patients in the placebo vs empagliflozin study.

In this week's Homerun Slides, the vital stats of patients on the placebo and empagliflozin 10- and 25-gram study.

In this week's Homerun Slides, the baseline characteristics of the randomized, placebo-controlled cardiovascular outcome trial of empagliflozin.

In this week's Homerun Slides, EMPA-REG Outcome, examining the long-term effects of empagliflozin versus using a placebo on the heart and mortality risk in patients with type 2.

In this week's Homerun Slides: EMPA-REG Outcome Trial Part 1: Meta-analysis of intensive glucose control in T2DM.